Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report

doi:10.1186/1752-1947-3-9330

Home
/
Papers
/
Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report

Journal Article•DOI•

Psammocarcinoma of ovary with serous cystadenofibroma of contralateral ovary: a case report

Deepali Jain¹, L Akhila¹, Vibha Kawatra¹, Pallavi Aggarwal¹, Nita Khurana¹ - Show less +1 more•Institutions (1)

Maulana Azad Medical College¹

15 Dec 2009-Journal of Medical Case Reports (BioMed Central)-Vol. 3, Iss: 1, pp 9330-9330

TL;DR: This is the rare case describing coexistence of this very rare malignant serous epithelial tumor with a benign serous cystadenofibroma of contralateral ovary in a 55 year old Asian Indian female.

read less

Abstract: Introduction Psammocarcinoma of ovary is a rare serous neoplasm characterized by extensive formation of psammoma bodies, invasion of ovarian stroma, peritoneum or intraperitoneal viscera, and moderate cytological atypia. Extensive medlar search showed presence of only 28 cases of psammocarcinoma of ovary reported till date.

...read moreread less

Content maybe subject to copyright Report

Citations

PDF

Open Access

More filters

Psammocarcinome séreux agressif de l'ovaire : à propos d'un cas et revue de la littérature Serous aggressive psammocarcinoma of the ovary: a case report and review of literature

[...]

M. Oukabli, K. Andaloussi, A. Boudhas, N. Harchichi, A. Albouzidi - Show less +1 more

01 Jan 2012

TL;DR: A new case of aggressive psammocarcinoma of ovary in 65 years old woman is reported, linked to a better prognosis than conventional serous adenocarcine.

...read moreread less

Abstract: Psammocarcinoma of ovary is a rare serous neo- plasm characterized by extensive formation of psammoma bodies with ovarian stromal invasion. Rarely aggressive with invasion of the peritoneum or intraperitoneal viscera, it is linked to a better prognosis than conventional serous adenocarcinoma. It is characterized by a tumor cells with little cytological atypia and a low nuclear grade. Extensive medlar search showed presence of only 29 cases of psammo- carcinoma of ovary reported till date. A new case of aggres- sive psammocarcinoma of ovary in 65 years old woman is reported.

...read moreread less

Journal Article•DOI•

Immunohistochemical study of ovarian psammocarcinoma: Report of a rare case.

[...]

Vandana L. Gaopande, Avinash R Joshi, Gayatri S Pathak, Bageshri P Gogate

01 Apr 2016-Taiwanese Journal of Obstetrics & Gynecology

TL;DR: Psammocarcinoma is a rare variant of serous carcinoma of the ovaries and has a favourable prognosis resembling that of serious borderline tumors, and a 60-year-old woman with a pelvic mass 20weeks size was offered.

...read moreread less

Abstract: Psammocarcinoma is a rare variant of serous carcinoma of the ovaries and has a favourable prognosis resembling that of serous borderline tumors [1]. A 60-year-old woman had a pelvic mass 20weeks size. Magnetic resonance imaging (MRI) showed bilateral ovarian cysts with suspicious peritoneal deposits (Figure. 1A). Carbohydrate antigen 125 level was 1300 U/mL. Peritoneal fluid cytology showed large cell groups with high nucleocytoplasmic ratio, irregular nuclear borders, and indistinct nucleoli. A single psammoma body (PB) was detected (Figure 1B). A diagnosis of ovarian carcinoma was offered. Intraoperatively, bilateral large cystic ovarian masses were seen with thickened omentum and multiple subdiaphragmatic deposits. A biopsy of the omental deposits showed tumor composed of small cuboidal to round cells arranged in a papillary, cribriform pattern. The cells showed minimal pleomorphism and scant mitotic figures. Abundant PBs were scattered throughout the fibrous stroma and in the tips of the papillae (Figure 1C). A diagnosis of metastatic deposits of ovarian psammocarcinoma, International Federation of Gynecology and Obstetrics (FIGO) Stage IIIc was given. Cytokeratin 7 and epithelial membrane antigen showed strong immunoreactivity in tumor cells (Figure 1D and 1E) and none for cytokeratin 20, calretinin, and desmin. Immunoreactivity for estrogen receptors was seen in 75% of tumor cells (Figure 1F). The patient was given tamoxifen and chemotherapy. Patients with psammocarcinoma range in age from 36 years to 76 years (mean age 57 years) [1]. Psammocarcinoma shows: (1)

...read moreread less

Cites background from "Psammocarcinoma of ovary with serou..."

...Elevated levels of carbohydrate antigen 125 are reported in ovarian as well as peritoneal psammocarcinoma [3,5]....
[...]

Journal Article•DOI•

Psammocarcinome séreux agressif de l’ovaire : à propos d’un cas et revue de la littérature

[...]

M. Oukabli, K. Andaloussi, A. Boudhas, N. Harchichi, Abderrahmane Albouzidi - Show less +1 more

10 Apr 2012-Journal Africain Du Cancer \/ African Journal of Cancer

TL;DR: In this paper, a nouveau case of psammocarcinome sereux de lovaire was reported in a 65-year-old patient with colorectal cancer.

...read moreread less

Abstract: Le psammocarcinome de l’ovaire est un adenocarcinome sereux rare caracterise par sa richesse en calcospherites avec invasion de stroma ovarien. C’est une tumeur rarement agressive avec invasion du peritoine ou des visceres intraperitoneaux. Elle est liee a un meilleur pronostic que l’adenocarcinome sereux conventionnel et se caracterise par des cellules tumorales presentant peu d’atypies et un faible grade nucleaire. Une large revue de la litterature a montre que seulement 29 cas ont ete rapportes jusqu’en decembre 2009. Nous rapportons un nouveau cas de psammocarcinome sereux de l’ovaire dans sa forme agressive chez une patiente de 65 ans.

...read moreread less

References

PDF

Open Access

More filters

Journal Article•DOI•

Case Report and Literature Review

[...]

James E. Spoden, Robert M. Bumsted, Emory D. Warner

01 May 1980-Annals of Otology, Rhinology, and Laryngology

TL;DR: A case of the chondroid variant of chordoma is presented and the differentiating features of this entity are discussed on a clinical and histopathologic basis.

...read moreread less

Abstract: A case of the chondroid variant of chordoma is presented. The differentiating features of this entity are discussed on a clinical and histopathologic basis. A review of the topic of chordoma is also provided.

...read moreread less

1,127 citations

Journal Article•DOI•

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

[...]

Nathalie L.G. Sieben¹, Patricia Macropoulos², Guido M.J.M. Roemen¹, Sandra M. Kolkman-Uljee³, Gert Jan Fleuren³, Rifat Houmadi², Tim C. Diss², Bretta Warren⁴, Mudher Al Adnani², Anton F.P.M. de Goeij¹, Thomas Krausz⁴, Adrienne M. Flanagan² - Show less +8 more•Institutions (4)

Maastricht University¹, University College London², Leiden University³, University of Chicago⁴

01 Mar 2004-The Journal of Pathology

TL;DR: The finding that at least 60% of serous borderline tumours harbour mutations in two members of the ERK‐MAP‐kinase pathway compared with 12% of high‐grade serous carcinomas (BRAF 0%, KRAS 12%) indicates that the majority of serious borderline tumoured tumours do not progress to serious carcinomas.

...read moreread less

Abstract: Genes of the RAF family, which mediate cellular responses to growth signals, encode kinases that are regulated by RAS and participate in the RAS/RAF/MEK/ERK/MAP-kinase pathway. Activating mutations in BRAF have recently been identified in melanomas, colorectal cancers, and thyroid and ovarian tumours. In the present study, an extensive characterization of BRAF and KRAS mutations has been performed in 264 epithelial and non-epithelial ovarian neoplasms. The epithelial tumours ranged from adenomas and borderline neoplasms to invasive carcinomas including serous, mucinous, clear cell, and endometrioid lesions. It is shown that BRAF mutations in ovarian tumours occur exclusively in low-grade serous neoplasms (33 of 91, 36%); these included serous borderline tumours (typical and micropapillary variants), an invasive micropapillary carcinoma and a psammocarcinoma. KRAS mutations were identified in 26 of 91 (29.5%) low-grade serous tumours, 7 of 49 (12%) high-grade serous carcinomas, 2 of 6 mucinous adenomas, 22 of 28 mucinous borderline tumours, and 10 of 18 mucinous carcinomas. Of note, two serous borderline tumours were found to harbour both BRAF and KRAS mutations. The finding that at least 60% of serous borderline tumours harbour mutations in two members of the ERK-MAP-kinase pathway (BRAF 36%, KRAS 30%) compared with 12% of high-grade serous carcinomas (BRAF 0%, KRAS 12%) indicates that the majority of serous borderline tumours do not progress to serous carcinomas. Furthermore, no BRAF mutations were detected in the other 173 ovarian tumours in this study.

...read moreread less

251 citations

"Psammocarcinoma of ovary with serou..." refers background in this paper

...Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours....
[...]
...The molecular features of psammocarcinoma include mutations of a gene belong to the cancer related RAF family, that is BRAF [19]....
[...]

Two Case Reports and Review of the Literature

[...]

Joanne Kurtzberg, Henry S. Friedman, Thomas R. Kinney, John M. Falletta

01 Jan 1987

155 citations

Journal Article•DOI•

Serous psammocarcinoma of the ovary and peritoneum

[...]

C. B. Gilks¹, Debra A. Bell, Robert E. Scully•Institutions (1)

University of British Columbia¹

01 Apr 1990-International Journal of Gynecological Pathology

TL;DR: The clinical behavior of psammocarcinoma more closely resembles that of borderline serous tumors than of serous carcinomas of the usual type, following a protracted course and being associated with a relatively favorable prognosis.

...read moreread less

Abstract: We report 11 cases of serous psammocarcinoma, a rare variant of serous carcinoma characterized by massive psammoma body formation and low-grade cytological features. The patients ranged in age from 36 to 76 (mean of 57) years. The tumors were stage three in every case (three stage IIIA, seven stage IIIB, and one stage IIIC). Eight of the patients had ovarian psammocarcinomas with ovarian tumors measuring 5-22 (mean of 11) cm in diameter; the other three patients had primary peritoneal psammocarcinomas. The surfaces of the ovarian tumors were smooth and intact in seven of eight ovarian psammocarcinomas. Cysts were present in six of eight ovarian tumors, and the solid portions were typically gritty or granular. Necrosis was not seen. Microscopically there was destructive invasion of ovarian stroma or vascular invasion in the ovarian tumors; the extraovarian tumor implants were invasive of intraperitoneal viscera in five cases. The epithelium was arranged in small nests with no areas of solid epithelial proliferation, and at least 75% of the epithelial nests were associated with psammoma body formation. No more than moderate nuclear atypicality was identified in any case. No mitotic figures were found in 10 of the tumors, with a single mitotic figure identified in the other tumor. Follow-up data for more than 1 year was available for six patients, with two patients lost to follow-up and three patients followed without evidence of recurrence for less than 1 year. One patient died of tumor 6 1/2 years after presentation, and five patients were alive without evidence of recurrent tumor 3-10 (mean of 8.3) years after presentation. Although based on a small number of cases, these data suggest that the clinical behavior of psammocarcinoma more closely resembles that of borderline serous tumors than of serous carcinomas of the usual type, following a protracted course and being associated with a relatively favorable prognosis.

...read moreread less

120 citations

Journal Article•DOI•

Psammocarcinoma with an aggressive course

[...]

Sarah Poggi¹, Robert E. Bristow¹, Roberta K. Nieberg¹, Jonathon S. Berek¹•Institutions (1)

University of California, Los Angeles¹

01 Oct 1998-Obstetrics & Gynecology

TL;DR: This case report of an aggressive course of this disease is presented to alert others that psammocarcinoma may not always follow a benign course and patients with this disease should have optimal tumor debulking.

...read moreread less

32 citations

"Psammocarcinoma of ovary with serou..." refers background in this paper

...Literature search showed presence of only 28 cases of psammocarcinoma of ovary reported till date (Table 1) [1-17]....
[...]
...In the case reported by Poggi et al [5] no adjuvant therapy was given because of the supposed indolent Computed tomography scan shows calcified abdominopelvic mass (a); gross photograph shows gritty and firm tumor (b); on histological examin tion, tumor reveals extensive psammoma bodies which are surrounded by ingle layer of cytologically bland cub idal or l w colum ar epit elium (c-f) H&E cx40; dx100; ex400; fx600Figure 1 Computed tomography scan shows calcified abdominopelvic mass (a); gross photograph shows gritty and firm tumor (b); on histological examination, tumor reveals extensive psammoma bodies which are surrounded by single layer of cytologically bland cuboidal or low columnar epithelium (c-f) H&E cx40; dx100; ex400; fx600....
[...]
...The right ovary measured 7 × 6 × 2 cms. Cut Page 1 of 6 (page number not for citation purposes) P ag e 2 of 6 (p ag e nu m be r n ot fo r c ita tio n pu rp os es ) Follow up Remarks 1-died 3- lost FU 4- free of disease 42 months NED Adolescent NED 12 months NED Family history of epithelial cancer positive Recurrence 18 months Aggressive, with Cystadenofibromata 2 years NED Omental and peritoneal implant NED after 1 year Bilateral, omental nodule showed the features of invasive implant Recovered Bilateral with cysadenofibromata NA Aggressive NED 4 months stable Jo ur na l o f M ed ic al C as e R ep or ts 2 00 9, 3 :9 33 0 ht tp :// w w w .jm ed ic al ca se re po rts .c om /c on te nt /3 /1 /9 33 0 Table 1: Literature review of primary ovarian psammocarcinomas Author Year No. of cases Age Clinical features CA- 125 units/ml FIGO stage Surgery Chemothearpy Gilks et al [1] 1990 8 36 to 76 (mean of 57) Abdominal pain NA III TAH+ BSO (4 cases) LSO(2 cases) BSO(2 cases) Oment (3/8 cases) Y (1 patient) Kelley et al [2] 1995 1 18 Abdominal pain 25 IIIC TAH, BSO, oment, Y Pakos et al [3] (German) 1997 1 49 Mass in the lower abdomen IA BSO N Powell et al [4] 1998 1 59 Abdominal pain and increasing abdominal girth 118 IIIB TAH, BSO, oment N Poggi et al [5] 1998 1 66 Abdominal Pain nausea vomiting NA IIIB BSO, oment N Cobellis et al [6] 2003 1 48 Referred for leiomyomata uteri Normal IIIA TAH, BSO, oment N Giordano et al [7] 2005 1 66 Abdomino-pelvic mass Elevated IIIB TAH, BSO, oment, Y Rattenmaier et al [8] 2005 1 70 Malaise and abdominal discomfort 25,000 NA AH, BSO N Radin et al [9] 2005 1 60 Diffuse abdominal pain, bloating, diarrhea, and low back pain, 65.2 III Laparotomy, tumor debulking Y Vimplis et al[10] 2006 1 63 Abdominal discomfort and increasing abdominal girth 1,133 IIIB BSO,, SH, oment, Y Hiromura et al [11] 2007 1 73 Lower abdominal distention and pain 464 IIIC AH, BSO, and oment Y of 6 (p ag e nu m be r n ot fo r c ita tio n pu rp os es ) Jo ur na l o f M ed ic al C as e R ep or ts 2 00 9, 3 :9 33 0 ht tp :// w w w .jm ed ic al ca se re po rts .c om /c on te nt /3 /1 /9 33 0 Journal of Medical Case Reports 2009, 3:9330 http://www.jmedicalcasereports.com/content/3/1/9330 section was solid and cystic with cysts ranging in size from 0.4 to 0.5 cm....
[...]
...Earlier, association of psammocarcinoma with cystadenofibroma has been documented [5,8]....
[...]
...In the case reported by Poggi et al [5] no adjuvant therapy was given because of the supposed indolent...
[...]